Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

immune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung and gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materia
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... June 22, 2007 /PRNewswire/ -- MAP,Pharmaceuticals, Inc. today ... its Unit Dose Budesonide (UDB) pediatric asthma therapy,clinical ... Lutfi Kirdar,Convention and Exhibition Center in Istanbul, Turkey. ... and safety,of a novel submicron particle formulation of ...
... Announces Bioinformatics Partnership with,Illumina , BEYOND GENOME ... a leading developer of lab and data ... announced that,it has penned an agreement with ... participant in IlluminaConnect, a,bioinformatics software program established ...
Cached Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Oxygen", as it is known by researchers at the Norwegian ... is gained on the pitch thanks to their new system ... the Journal of Sports Medicine and has enjoyed ... improve the players, sprint, jump and endurance. , "With ...
... near manufacturing industries, a breath of air may ... location, finds a recent study involving a Kansas ... of geology at Kansas State University, along with ... School of Public Health and Department of Environmental ...
... Measurement of pressure within the eye, or intraocular pressure (IOP), ... in patients with glaucoma are believed to be related to ... to the optic nerve and vision. The clinical assessment ... daytime hours. In a new study, parents using the ...
... Steven Reinberg HealthDay Reporter , TUESDAY, March ... who have psychiatric disorders, especially post-traumatic stress disorder, are ... narcotic painkillers, a new study finds. Use of ... Vicodin, can become addictive and cause more serious problems, ...
... (HealthDay News) -- Most stroke patients undergo both CT and ... rising costs of stroke care in the United States, a ... from more than 600,000 patients diagnosed with stroke between 1999 ... of the patients who had MRI scans also had CT ...
... (HealthDay News) -- When it comes to wine, a new study ... on many consumers. The professionals seem to have a much ... State University explained. As a result, wine experts are able to ... people just can,t taste. "What we found is that the ...
Cached Medicine News:Health News:1 more 'player' on the pitch thanks to a new training method 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 3Health News:Home measurement of eye pressure in children may improve management of glaucoma 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: